1-3 of 3
Karel Hahlen, MD, PhD
Close
Sort by
Journal Articles

FLT3 and KIT Mutated Pediatric Acute Myeloid Leukemia (AML) Samples Are More Sensitive In Vitro to the Tyrosine Kinase Inhibitor SU11657.

Bianca F. Goemans, MD, Christian M. Zwaan, MD,PhD, Desiree de Lange, Jacqueline Cloos, PhD, Dirk Reinhardt, MD,PhD, Karel Hahlen, MD,PhD, Brenda E.S. Gibson, MD,PhD, Ursula Creutzig, MD,PhD, GertJan J.L. Kaspers, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 1359.
https://doi.org/10.1182/blood.V108.11.1359.1359
Published: 2006
Journal Articles

Large Interindividual Differences in In Vitro Calicheamicin Sensitivity May Underly Gemtuzumab Ozogamicin Resistance in Acute Myeloid Leukemia (AML).

Bianca F. Goemans, MD, Gertjan J.L. Kaspers, MD, PhD, Susanne J.H. Vijverberg, BSc, Anne H. Loonen, Ursula Creutzig, MD, PhD, Karel Hahlen, MD, PhD, Dirk Reinhardt, MD, PhD, Brenda E.S. Gibson, MD, PhD, Jacqueline Cloos, PhD, Christian M. Zwaan, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 107.
https://doi.org/10.1182/blood.V106.11.107.107
Published: 2005
Journal Articles

Outcome of the Rotterdam-84 CNS-ALL Chemotherapy Protocol without Radiotherapy for Isolated Central Nervous System Relapsed Acute Lymphoblastic Leukemia.

Auke Beishuizen, MD, PhD, Femke K. Aarsen, MA, Jeanette E.W.M. van Dongen, PhD, MA, Isabelle C. Streng, MA, Rob Pieters, MD, PhD, Karel Hahlen, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 1955.
https://doi.org/10.1182/blood.V104.11.1955.1955
Published: 2004